These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38026755)

  • 21. Amyloid-Related Imaging Abnormalities: An Update.
    Roytman M; Mashriqi F; Al-Tawil K; Schulz PE; Zaharchuk G; Benzinger TLS; Franceschi AM
    AJR Am J Roentgenol; 2023 Apr; 220(4):562-574. PubMed ID: 36321981
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease.
    Joseph-Mathurin N; Llibre-Guerra JJ; Li Y; McCullough AA; Hofmann C; Wojtowicz J; Park E; Wang G; Preboske GM; Wang Q; Gordon BA; Chen CD; Flores S; Aggarwal NT; Berman SB; Bird TD; Black SE; Borowski B; Brooks WS; Chhatwal JP; Clarnette R; Cruchaga C; Fagan AM; Farlow M; Fox NC; Gauthier S; Hassenstab J; Hobbs DA; Holdridge KC; Honig LS; Hornbeck RC; Hsiung GR; Jack CR; Jimenez-Velazquez IZ; Jucker M; Klein G; Levin J; Mancini M; Masellis M; McKay NS; Mummery CJ; Ringman JM; Shimada H; Snider BJ; Suzuki K; Wallon D; Xiong C; Yaari R; McDade E; Perrin RJ; Bateman RJ; Salloway SP; Benzinger TLS; Clifford DB;
    Ann Neurol; 2022 Nov; 92(5):729-744. PubMed ID: 36151869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
    Piazza F; Winblad B
    J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.
    Klein G; Delmar P; Voyle N; Rehal S; Hofmann C; Abi-Saab D; Andjelkovic M; Ristic S; Wang G; Bateman R; Kerchner GA; Baudler M; Fontoura P; Doody R
    Alzheimers Res Ther; 2019 Dec; 11(1):101. PubMed ID: 31831056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA.
    Sin MK; Zamrini E; Ahmed A; Nho K; Hajjar I
    J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis.
    Sperling R; Salloway S; Brooks DJ; Tampieri D; Barakos J; Fox NC; Raskind M; Sabbagh M; Honig LS; Porsteinsson AP; Lieberburg I; Arrighi HM; Morris KA; Lu Y; Liu E; Gregg KM; Brashear HR; Kinney GG; Black R; Grundman M
    Lancet Neurol; 2012 Mar; 11(3):241-9. PubMed ID: 22305802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis.
    Arrighi HM; Barakos J; Barkhof F; Tampieri D; Jack C; Melançon D; Morris K; Ketter N; Liu E; Brashear HR
    J Neurol Neurosurg Psychiatry; 2016 Jan; 87(1):106-12. PubMed ID: 25669746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease.
    Avgerinos KI; Ferrucci L; Kapogiannis D
    Ageing Res Rev; 2021 Jul; 68():101339. PubMed ID: 33831607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic anti-amyloid β antibodies cause neuronal disturbances.
    Adhikari UK; Khan R; Mikhael M; Balez R; David MA; Mahns D; Hardy J; Tayebi M
    Alzheimers Dement; 2023 Jun; 19(6):2479-2496. PubMed ID: 36515320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease.
    Carlson C; Siemers E; Hake A; Case M; Hayduk R; Suhy J; Oh J; Barakos J
    Alzheimers Dement (Amst); 2016; 2():75-85. PubMed ID: 27239538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti-Amyloid-β Therapy.
    Agarwal A; Gupta V; Brahmbhatt P; Desai A; Vibhute P; Joseph-Mathurin N; Bathla G
    Radiographics; 2023 Sep; 43(9):e230009. PubMed ID: 37651273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities.
    Hardy J; Schott JM
    Neurology; 2024 Feb; 102(3):e208096. PubMed ID: 38165303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-Aβ Autoantibodies in Amyloid Related Imaging Abnormalities (ARIA): Candidate Biomarker for Immunotherapy in Alzheimer's Disease and Cerebral Amyloid Angiopathy.
    DiFrancesco JC; Longoni M; Piazza F
    Front Neurol; 2015; 6():207. PubMed ID: 26441825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease.
    Honig LS; Barakos J; Dhadda S; Kanekiyo M; Reyderman L; Irizarry M; Kramer LD; Swanson CJ; Sabbagh M
    Alzheimers Dement (N Y); 2023; 9(1):e12377. PubMed ID: 36949897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Evaluation of Amyloid-Related Imaging Abnormalities in Bapineuzumab Phase III Studies.
    Brashear HR; Ketter N; Bogert J; Di J; Salloway SP; Sperling R
    J Alzheimers Dis; 2018; 66(4):1409-1424. PubMed ID: 30412493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imaging of Amyloid-Related Imaging Abnormalities (ARIA).
    Urbach H; Linn J; Hattingen E; Fiebach J
    Rofo; 2024 Apr; 196(4):363-369. PubMed ID: 37995736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease.
    Salloway S; Chalkias S; Barkhof F; Burkett P; Barakos J; Purcell D; Suhy J; Forrestal F; Tian Y; Umans K; Wang G; Singhal P; Budd Haeberlein S; Smirnakis K
    JAMA Neurol; 2022 Jan; 79(1):13-21. PubMed ID: 34807243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amyloid-Related Imaging Abnormalities in an Aged Squirrel Monkey with Cerebral Amyloid Angiopathy.
    Heuer E; Jacobs J; Du R; Wang S; Keifer OP; Cintron AF; Dooyema J; Meng Y; Zhang X; Walker LC
    J Alzheimers Dis; 2017; 57(2):519-530. PubMed ID: 28269776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MRI in the new era of antiamyloid mAbs for the treatment of Alzheimer's disease.
    Filippi M; Cecchetti G; Agosta F
    Curr Opin Neurol; 2023 Aug; 36(4):239-244. PubMed ID: 37382144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis.
    Jeremic D; Navarro-López JD; Jiménez-Díaz L
    Ageing Res Rev; 2023 Sep; 90():102012. PubMed ID: 37423541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.